Phase 1 Evaluation of ZW191 in Patients with Advanced Solid Tumors

The primary objective of this Phase 1 study is to evaluate the safety and tolerability of **ZW191** in participants with **advanced solid tumors**. This is clinically relevant as it aims to determine the appropriate dosage and identify any potential adverse effects, which are critical steps in the development of new therapeutic options for patients with these types of malignancies.

The clinical trial involves a total of **130 participants** diagnosed with **advanced solid tumors**. The study population includes both male and female subjects, with an age range spanning from **18 to 64 years**. Participants were selected without targeting any vulnerable populations, ensuring a diverse representation of the general adult population. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The selection process aimed to include individuals who meet the general health criteria for participation in a study of this nature, although specific inclusion or exclusion criteria were not provided by the sponsor.

The clinical trial is a **Phase 1** study designed to evaluate the investigational product ZW191 in participants with **advanced solid tumors**. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The estimated duration of the trial spans from the recruitment start date on May 1, 2025, to the anticipated end date on February 26, 2027.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to confirm the diagnosis of advanced solid tumors and ensure the absence of exclusion criteria. Following successful screening, participants will be randomized and commence the treatment phase, with regular follow-up visits scheduled to monitor safety, tolerability, and any potential adverse events. These follow-up visits will occur at predetermined intervals throughout the study duration.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial, during which final assessments will be conducted to gather data on the primary and secondary endpoints. The expected length of participant involvement will vary depending on individual response and the overall study timeline. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, withdrawal of consent, or any other protocol-defined criteria that compromise participant safety or data integrity.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on May 1, 2025, with an estimated completion date of February 26, 2027. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize a combination of clinical observations and laboratory tests to gather initial efficacy data. The data collection and analysis will adhere to standard clinical trial protocols, ensuring rigorous and systematic evaluation of the investigational product's effects. The trial will employ validated tools and instruments appropriate for the disease under investigation, although these are not specified in the available data. The results will contribute to the understanding of the investigational product's potential therapeutic benefits and inform subsequent trial phases.